BACKGROUND: Placenta growth factor (PlGF) plays an important role in pathologic angiogenesis and is believed to be an independent biomarker in patients with coronary artery disease. However, little is known regarding the regulation of PlGF expression in heart tissue. METHODS: We determined expression changes in PlGF and its receptor, VEGFR1, in normal and abnormal biopsies from human cardiac allografts and in cardiomyocytes cultured under hypoxia or cyclical stretch conditions. RESULTS: Human donor myocardium and biopsies from allografts without fibrin deposits expressed PlGF and VEGFR1 mRNA. Biopsies (n = 7) with myocardial fibrin, elevated serum cardiac troponin I titers (p < 0.03) and cellular infiltrates (p < 0.05) expressed 1.6-fold more PlGF mRNA than biopsies from allografts without fibrin (n = 11; p < 0.05). PlGF protein was localized in cardiomyocytes, extracellular matrix and some microvessels in areas with fibrin deposition. VEGFR1 mRNA expression was not different between groups. Cultured neonatal rat cardiomyocytes constitutively expressed PlGF/VEGFR1 under normoxia. PlGF expression was increased 3.88 +/- 0.62-fold after 12 hours (n = 6; p </= 0.05) and 3.64 +/- 0.41-fold after 24 hours of hypoxia (n = 6; p <or= 0.05). Shorter periods of hypoxia, conditioned media from hypoxic cells and cyclical stretch did not significantly alter PlGF or VEGFR1 expression. CONCLUSIONS: Cardiomyocyte PIGF expression is upregulated by hypoxia in vitro and its expression increases significantly in allografts with myocardial damage. Collectively, these results provide important temporal and spatial evidence that endogenous PlGF may facilitate cardiac healing after myocardial hypoxia/ischemia.
BACKGROUND:Placenta growth factor (PlGF) plays an important role in pathologic angiogenesis and is believed to be an independent biomarker in patients with coronary artery disease. However, little is known regarding the regulation of PlGF expression in heart tissue. METHODS: We determined expression changes in PlGF and its receptor, VEGFR1, in normal and abnormal biopsies from human cardiac allografts and in cardiomyocytes cultured under hypoxia or cyclical stretch conditions. RESULTS:Humandonor myocardium and biopsies from allografts without fibrin deposits expressed PlGF and VEGFR1 mRNA. Biopsies (n = 7) with myocardial fibrin, elevated serum cardiac troponin I titers (p < 0.03) and cellular infiltrates (p < 0.05) expressed 1.6-fold more PlGF mRNA than biopsies from allografts without fibrin (n = 11; p < 0.05). PlGF protein was localized in cardiomyocytes, extracellular matrix and some microvessels in areas with fibrin deposition. VEGFR1 mRNA expression was not different between groups. Cultured neonatal rat cardiomyocytes constitutively expressed PlGF/VEGFR1 under normoxia. PlGF expression was increased 3.88 +/- 0.62-fold after 12 hours (n = 6; p </= 0.05) and 3.64 +/- 0.41-fold after 24 hours of hypoxia (n = 6; p <or= 0.05). Shorter periods of hypoxia, conditioned media from hypoxic cells and cyclical stretch did not significantly alter PlGF or VEGFR1 expression. CONCLUSIONS: Cardiomyocyte PIGF expression is upregulated by hypoxia in vitro and its expression increases significantly in allografts with myocardial damage. Collectively, these results provide important temporal and spatial evidence that endogenous PlGF may facilitate cardiac healing after myocardial hypoxia/ischemia.
Authors: P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico Journal: Nat Med Date: 2001-05 Impact factor: 53.440
Authors: F J Giordano; H P Gerber; S P Williams; N VanBruggen; S Bunting; P Ruiz-Lozano; Y Gu; A K Nath; Y Huang; R Hickey; N Dalton; K L Peterson; J Ross; K R Chien; N Ferrara Journal: Proc Natl Acad Sci U S A Date: 2001-05-01 Impact factor: 11.205
Authors: C A Labarrere; R J Torry; D R Nelson; S J Miller; D E Pitts; P C Kirlin; H G Halbrook Journal: Am J Cardiol Date: 2001-02-15 Impact factor: 2.778
Authors: Brian D Kelly; Sean F Hackett; Kiichi Hirota; Yuji Oshima; Zheqing Cai; Shannon Berg-Dixon; Ashley Rowan; Zhijiang Yan; Peter A Campochiaro; Gregg L Semenza Journal: Circ Res Date: 2003-10-23 Impact factor: 17.367
Authors: Christopher Heeschen; Stefanie Dimmeler; Stephan Fichtlscherer; Christian W Hamm; Juergen Berger; Maarten L Simoons; Andreas M Zeiher Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: Monica Autiero; Johannes Waltenberger; Didier Communi; Andrea Kranz; Lieve Moons; Diether Lambrechts; Jens Kroll; Stephane Plaisance; Maria De Mol; Françoise Bono; Stefanie Kliche; Guido Fellbrich; Kurt Ballmer-Hofer; Domenico Maglione; Ulrike Mayr-Beyrle; Mieke Dewerchin; Saskia Dombrowski; Danica Stanimirovic; Paul Van Hummelen; Christoph Dehio; Daniel J Hicklin; Graziella Persico; Jean-Marc Herbert; David Communi; Masabumi Shibuya; Désiré Collen; Edward M Conway; Peter Carmeliet Journal: Nat Med Date: 2003-07 Impact factor: 53.440
Authors: Laura Tudisco; Floriana Della Ragione; Valeria Tarallo; Ivana Apicella; Maurizio D'Esposito; Maria Rosaria Matarazzo; Sandro De Falco Journal: Epigenetics Date: 2014-02-06 Impact factor: 4.528
Authors: Julia E Brittain; Ben Hulkower; Susan K Jones; Dell Strayhorn; Laura De Castro; Marilyn J Telen; Eugene P Orringer; Alan Hinderliter; Kenneth I Ataga Journal: Blood Date: 2009-12-29 Impact factor: 22.113
Authors: Federica Accornero; Jop H van Berlo; Matthew J Benard; John N Lorenz; Peter Carmeliet; Jeffery D Molkentin Journal: Circ Res Date: 2011-06-02 Impact factor: 17.367